# pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

> **NCT04090528** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 60 (actual)

## Conditions studied

- Castration-resistant Prostate Cancer
- Metastatic Cancer
- Prostate Cancer

## Interventions

- **BIOLOGICAL:** pTVG-HP
- **BIOLOGICAL:** pTVG-AR
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04090528
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-21
- **Primary completion:** 2024-11-24
- **Final completion:** 2026-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- Merck Sharp & Dohme LLC
- Madison Vaccines Incorporated
- Prostate Cancer Foundation

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04090528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04090528, "pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT04090528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*